AbbVie's Elahere demonstrates 62.7% response rate in platinum-sensitive ovarian cancer

AbbVie [presented Phase II results](https://www.prnewswire.com/news-releases/abbvie-showcases-latebreaking-phase-2-data-for-mirvetuximab-soravtansine-gynx-elahere-in-platinumsensitive-ovarian-cancer-psoc-at-sgo-2026-302739847.html) for mirvetuximab soravtansine (Elahere) in folate receptor alpha (FRα)-positive, recurrent platinum-sensitive ovarian cancer at the SGO 2026 Annual Meeting. The open-label IMGN853-0420 trial reported a confirmed objective response rate of 62.7% (95% CI, 52.6–72.1) in the primary FRα ≥50% subgroup after six cycles of combination induction therapy, the company said. The 125-patient trial enrolled adults with FRα-positive recurrent platinum-sensitive high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer who had received one prior platinum-based chemotherapy regimen. Patients received mirvetuximab soravtansine plus carboplatin every three weeks for six to eight induction cycles, followed by single-agent mirvetuximab soravtansine continuation for those without disease progression. In the overall FRα ≥25% population, confirmed ORR after induction was 62.4% (95% CI, 53.3–70.9), and 81% of patients (101 of 125) proceeded to the monotherapy continuation phase. Median duration of response across the overall population was 11.2 months. Among patients who transitioned to single-agent continuation, ORR was 68% (95% CI, 59.1–76.1). In the approximately 49% of patients with prior PARP inhibitor (PARPi) exposure, ORR was 63.9% (95% CI, 50.6–75.8). The safety profile was consistent with prior mirvetuximab soravtansine studies; the most common treatment-related adverse events were low-grade ocular events, including corneal changes that were reversible in more than 90% of patients. Grade ≥3 treatment-related adverse events occurring in more than 5% of patients included neutropenia (15%), blurred vision (10%), thrombocytopenia (10%), cataract (6%), dry eye (5%), diarrhea (5%), and peripheral sensory neuropathy (5%). The [IMGN853-0420 trial (NCT05456685)](https://app.allsci.com/clinical-trial/ASC-CT-0000000029027-1.0-1745700230) is a multicenter, open-label, single-arm Phase II study; the absence of a randomized control arm limits interpretation of the response rates relative to standard platinum-based chemotherapy alone in this setting. Biomarker eligibility required confirmed FRα positivity using the Ventana FOLR1 Assay, restricting enrollment to patients with ≥25% tumor cells showing ≥2+ membrane intensity. The data reported reflect the end of the induction phase; progression-free survival and overall survival data were not reported at this readout. The combination of mirvetuximab soravtansine plus carboplatin followed by mirvetuximab soravtansine continuation is not approved in the US, the EU, or any other territory for this indication, and the safety and efficacy of this regimen in platinum-sensitive ovarian cancer have not been established. Mirvetuximab soravtansine is an antibody-drug conjugate comprising an FRα-binding antibody linked to the maytansinoid payload DM4, a tubulin inhibitor, and currently holds FDA approval for FRα-positive platinum-resistant epithelial ovarian cancer in patients who have received one to three prior systemic regimens. The IMGN853-0420 data extend the clinical evaluation of the molecule into the platinum-sensitive recurrence setting, where carboplatin-based doublets remain standard and PARP inhibitor maintenance has reshaped the treatment sequence; the 63.9% ORR observed in prior-PARPi patients is of particular note given published evidence that prior PARPi exposure reduces subsequent platinum sensitivity. Cross-trial comparisons are limited by differences in study design, duration, and patient populations. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/mirvetuximab-soravtansine-ovarian-cancer)